安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed . . .
Zodasiran is an RNA interference (RNAi) therapy targeting expression of ANGPTL3 in the liver
- Zodasiran for cholesterol and triglyceride lowering in . . . - Nature
Here we describe a 16-week phase 1 trial of zodasiran, an ANGPTL3‑targeting small interfering RNA, in patients on lipid-lowering therapy with either hyperlipidemia (with a placebo control arm
- Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in . . .
Zodasiran treatment was associated with dose-dependent placebo adjusted reductions in triglycerides, remnant cholesterol, LDL-C, ApoB, and Non-HDL-C across all dose levels in patients with mixed hyperlipidemia
- Study Details | NCT07037771 | A Phase 3 Study of Zodasiran in . . .
This multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of zodasiran subcutaneous (SC) injection in subjects 12 years of age and older with genetically or clinically diagnosed Homozygous familial hypercholesterolemia (HoFH)
- Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia
Zodasiran (ARO-ANG3) is an siRNA molecule that disrupts ex-pression of ANGPTL3 by degrading its mRNA and thereby inhibiting the hepatic synthesis and secretion of ANGPTL3
- Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients . . .
Zodasiran is a small interfering RNA (siRNA) that inhibits hepatic production of ANGPTL3 and has been shown to reduce circulating concentrations of ANGPTL3 and multiple atherogenic lipids in previous phase 1 and 2 studies, 10,11 and might be appropriate for the treatment of HoFH
- Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of . . .
Zodasiran, previously called ARO-ANG3, is a first-in-class investigational RNA interference (RNAi) therapeutic designed to reduce production of angiopoietin-like protein (ANGPTL3), which is a hepatocyte expressed regulator of lipid and lipoprotein metabolism with multiple potential modes of action, including inhibition of lipoprotein lipase
- Zodasiran reduces triglycerides and LDL-c in mixed dyslipidaemia
Zodasiran (formerly known as ARO-ANG3) is a novel siRNA molecule that suppresses hepatic ANGPTL3 gene expression Angiopoietin-like protein 3 (ANGPTL3) in turn inhibits lipoprotein and endothelial lipases and reduces hepatic uptake of remnant cholesterol
|
|
|